Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	183.61	99.19	102.99	100.71	184.43	143.58
Short-Term Investments	911.7	578.28	292.74	268.39	183.36	171.91
Cash & Short-Term Investments	1,095	677.46	395.73	369.1	367.79	315.49
Cash Growth	110.27%	71.19%	7.22%	0.36%	16.58%	21.95%
Receivables	2.37	-	-	1.41	10.26	0.85
Prepaid Expenses	23.77	9.54	8.81	7.29	4.36	4.25
Restricted Cash	2.1	3.5	7.9	7.3	-	-
Other Current Assets	11.68	4.97	4.03	20.2	2.19	1.78
Total Current Assets	1,135	695.47	416.47	405.3	384.6	322.37
Property, Plant & Equipment	429.26	431.29	335.56	168.59	66.02	47.02
Long-Term Investments	-	-	-	105.87	245.6	137.49
Other Intangible Assets	7.71	8.56	10.26	11.96	13.66	15.36
Other Long-Term Assets	1.31	4.48	3.26	0.22	0.27	0.26
Total Assets	1,573	1,140	765.55	691.94	710.15	522.5
Accounts Payable	9.98	11.39	35.87	2.87	9.46	6.83
Accrued Expenses	94.71	80.8	43.68	59.11	23.77	13.45
Current Portion of Long-Term Debt	65	-	-	-	-	-
Current Portion of Leases	6.78	6.34	10.56	2.78	2.25	1.1
Current Unearned Revenue	43.27	-	0.87	74.1	111.06	19.29
Other Current Liabilities	0.81	4.64	14.48	-	-	0.02
Total Current Liabilities	220.54	103.17	105.46	138.85	146.54	40.68
Long-Term Debt	561.2	734.54	268.33	-	-	-
Long-Term Leases	107.53	111.03	104.61	78.8	23.3	20.04
Long-Term Unearned Revenue	-	-	-	55.95	131.5	-
Total Liabilities	889.27	948.74	478.39	273.6	301.33	60.73
Common Stock	0.23	0.22	0.2	0.2	0.2	0.2
Additional Paid-In Capital	2,107	1,806	1,300	1,219	1,053	965.41
Retained Earnings	-1,428	-1,626	-1,026	-820.76	-644.69	-503.84
Comprehensive Income & Other	4.39	4.75	-3.22	-0.14	-0.07	0.02
Total Common Equity	683.32	185.44	271.34	398.52	408.82	461.78
Minority Interest	0.9	5.62	15.82	19.82	-	-
Shareholders' Equity	684.23	191.06	287.16	418.34	408.82	461.78
Total Liabilities & Equity	1,573	1,140	765.55	691.94	710.15	522.5
Total Debt	740.51	851.91	383.5	81.58	25.55	21.14
Net Cash (Debt)	354.8	-174.45	12.23	287.52	342.24	294.36
Net Cash Growth	193.08%	-	-95.75%	-15.99%	16.27%	13.78%
Net Cash Per Share	2.80	-1.46	0.11	2.73	3.30	2.92
Filing Date Shares Outstanding	138.1	124.43	107.43	106.01	104.53	102.76
Total Common Shares Outstanding	138.06	124.38	107.31	105.96	104.33	102.38
Working Capital	914.68	592.3	311.02	266.45	238.06	281.69
Book Value Per Share	4.95	1.49	2.53	3.76	3.92	4.51
Tangible Book Value	675.61	176.88	261.08	386.56	395.16	446.42
Tangible Book Value Per Share	4.89	1.42	2.43	3.65	3.79	4.36
Land	3	3	3	3	-	-
Buildings	248.89	75.99	-	-	-	-
Machinery	80.7	71.93	58.75	40.47	29.67	21.32
Construction In Progress	16.25	188.73	166.66	56.37	0.35	-
Leasehold Improvements	104.4	104.41	103.81	42.02	41.52	25.24

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q